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Abstract
Invasive meningococcal disease (IMD) is a severe bacterial infectious disease with high mortality and 
morbidity rates worldwide. In recent years, industrialised countries have implemented vaccines targeting 
IMD in their National Immunisation Programmes (NIPs). In 2002, the Netherlands successfully implemented 
a single dose of meningococcal serogroup C conjugate vaccine at the age of 14 months and performed a 
single catch-up for children ≤18 years of age. Since then the disease disappeared in vaccinated individuals. 
Furthermore, herd protection was induced, leading to a significant IMD reduction in non-vaccinated 
individuals. However, previous studies revealed that the current programmatic immunisation strategy was 
insufficient to protect the population in the foreseeable future. In addition, vaccines that provide protection 
against additional serogroups are now available. This paper describes to what extent the current strategy to 
prevent IMD in the Netherlands is still sufficient, taking into account the burden of disease and the latest 
scientific knowledge related to IMD and its prevention. In particular, primary MenC immunisation seems 
not to provide long-term protection, indicating a risk for possible recurrence of the disease. This can be 
combatted by implementing a MenC or MenACWY adolescent booster vaccine. Additional health benefits 
can be achieved by replacing the primary MenC by a MenACWY vaccine. By implementation of a recently 
licensed MenB vaccine for infants in the NIP, the greatest burden of disease would be targeted. This paper 
shows that optimisation of the immunisation strategy targeting IMD in the Netherlands should be considered 
and contributes to create awareness concerning prevention optimisation in other countries. 
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Invasive meningococcal disease (IMD) is a global health threat and has been a cause for serious concern for a number of years. This severe bacterial infectious disease, 
causing meningitis and sepsis, is caused by the bacterium 
Neisseria meningitidis, or the meningococcus, and has humans 
as its only reservoir. Over 90% of the cases are caused by 6 
serogroups: A, B, C, Y, W, and X.1 In industrialised countries, 
including the Netherlands, serogroups B (MenB), C (MenC) 
and Y (MenY) have mainly had the highest prevalence and 
caused major outbreaks and hyperendemic diseases since the 
1970s.2,3 Ten percent of the healthy people are asymptomatic 
carriers of the bacterium and contribute to transmitting the 
disease. 
Worldwide, IMD is associated with a high incidence. Annually, 
approximately 1.2 million cases are recorded worldwide; of 
which 7000 occur in Europe.4 Despite advances in antibiotic 
therapy and medical treatment, the mortality of IMD is 10% 
and death can occur within hours or days. Survivors of IMD 
have a 30% risk of serious long-term complications, such 
as hearing loss, skin scarring, brain damage, kidney failure, 
learning disabilities and other neurological abnormalities 
or limb amputations.5,6 The disease mainly affects infants 
and children (immature immune systems), but shows also 
increased rates among adolescents (highest carriage rates) 
and elderly (immunosenescence).6
Immunisation is considered the best strategy to prime and 
boost the immune system and prevent individuals from 
serious, life-threatening IMD.7 In addition, immunisation 
reduces the use of antibiotics and therewith the chance to 
develop antibiotic resistance of meningococci.8,9 The first 
meningococcal polysaccharide vaccine was approved in 1978. 
Since then, in industrialised countries, polysaccharide vaccines 
have been used to help prevent IMD in high-risk individuals 
(eg, asplenics) and travellers. Subsequently, despite notable 
differences between Europe and the United States/Canada 
in both epidemiology and vaccination strategy, since the 
beginning of the twentieth century, conjugated monovalent 
MenC and quadrivalent MenACWY vaccines have been 
introduced in National Immunisation Programmes (NIPs) 
of industrialised countries. In addition, one-off catch-ups to 
immunise adolescents lead to herd protection, as they are the 
group that carry meningococci. This significantly reduced the 
incidence and threat of this devastating disease, helped reduce 
healthcare costs to both patients and healthcare systems, and 
reduced profound neuropsychological consequences for the 
affected individuals and their families.6,10
A central issue in public health management is the validity 
of NIPs targeting IMD. In particular, current NIPs seem 
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to insufficiently protect in the near future due to waning 
antibody levels after primary MenC immunisation.11 
Furthermore, recently 2 vaccines targeting MenB IMD 
became available: 4CMenB (Bexsero®, GlaxoSmithKline) 
and LP2086 (Trumenba®, Pfizer) of which only 4CMenB 
is currently licensed in the European Union (EU). Also, in 
several countries increases in incidence are seen among 
MenY IMD and MenW IMD.8,12,13 As vaccines are available 
providing protection against these additional serogroups 
and meningococcal vaccines are also indicated for use in 
adolescents, alternative immunisation programmes should 
be considered. Despite these developments, only a limited 
number of countries updated their NIP. To illustrate, the 
Netherlands currently uses the same IMD immunisation 
strategy as was implemented in 2002. Therefore, in order to 
optimally protect individuals and the society against IMD, 
this paper validates the strength of the current preventive 
measures around IMD and examines the need for prevention 
optimisation and formulates recommendations to optimise 
the immunisation strategy, using the Netherlands as an 
example.
Change of Epidemiology in the Netherlands 
After the dramatic outbreak of MenC IMD at the beginning of 
the twentieth century,14 in 2002, the Netherlands introduced 
a MenC vaccine in the NIP for children 14 months of age and 
performed a single catch-up for children ≤18 years of age 
to provide direct protection to a large cohort and to induce 
herd immunity.15 It has been demonstrated that since the last 
decade, the incidence of all cases of IMD in the Netherlands 
has markedly declined: 717 cases were reported in 2001 and 
111 in 2013.14,16 The introduction of the MenC vaccine in 
particular, and the natural decline of incidence of MenB are 
contributing factors. In 2013, there were 6 cases of  MenC IMD, 
of which all were not vaccinated because of age or nationality, 
and there were 88 cases of MenB IMD was 88, of which the 
greatest burden was seen in infants and children. There were 
7 and 14 cases of respectively MenW and MenY IMD in 2013, 
and have, during recent years, slightly increased, particularly 
in adolescents. These trends are seen in most industrialised 
countries.8,12,13 Maintenance of enhanced surveillance results 
in a better understanding of the changing nature of the 
epidemiology,7,16 and detects possible outbreaks and losses 
in direct protection and herd protection.17 This is crucial for 
identifying extended optimal immunisation policies.
Evolving Immunisation Strategies 
Introduction of a MenC Adolescent Booster Vaccine to Tackle 
Waning Antibody Levels
An additional MenC booster dose could be considered to 
induce long-term protection against MenC IMD. While the 
MenC immunisation in the Netherlands was successful in 
decreasing the incidence of MenC IMD (277 cases in 2001 
and 6 in 2013),18 it fails to induce persistent protection.11,16,19 In 
particular, waning of antibody levels has been observed after 
primary immunisation of infants, which in turn is likely to 
result in a decline in herd protection.11,19-21 When MenC IMD 
returns into the population, especially adolescents seem to be 
at increased risk, as their antibody levels will have declined 
and they have the highest carriage rates increasing the 
transmission potential of the bacterium.11,20 These findings 
suggest that in the near future a potentially extensive group 
might be at risk of MenC IMD. Therefore, it is suggested that 
prevention against MenC IMD needs further optimisation. To 
tackle this waning immunity, implementation of an adolescent 
booster seems to evoke higher antibody levels, and long-term 
and possible lifelong protection.16 A Dutch study showed that 
administering a booster dose 9, 12, or 15 years after primary 
immunisation develops high protective antibody levels that 
are still at a sufficient level after one year.19 Furthermore, these 
results suggest that persisting individual protection increases 
with the age at which the booster is administered.19 
As illustrated in Table, recently, Canada, Spain, Ireland, 
Switzerland, and the United Kingdom introduced a MenC 
adolescent booster in their NIP to provide long-term 
protection.22-25 Furthermore, discussions are being held 
about the possible use of a MenC vaccine at the moment 
Table. Vaccines Targeting IMD Recommended to Healthy People in NIPs 
(August 2015)
Country Serogroup Age
Americas 
Canada
C 2 + 12 mon (2 doses)/12 mon (1 dose); 
5-11 y (catch-upa)
C or ACWY 12(-24) y (booster)
B >2 mon
US ACWY 11-12 y (1 dose); 16 y (booster)
Europe
Austria C or ACWY 12-14 mon (1 dose) – not funded 
ACWY 11-13 y (booster)
Belgium C 13-18 mon (1 dose)
Cyprus C 12-13 mon (1 dose) 
France C 12-23 mon (1 dose); 2-24 y (catch-upa)
Germany C 11-23 mon; 2-24 y (catch-upa)
Greece 
C 2 + 4 + 6 mon - 5 y (3 doses)
ACWY 11 y (booster)
Iceland C 6 + 8 mon (2 doses)
Ireland C 4 + 13 mon (2 doses); 12-13 y (booster)
Italy C 13-15 mon (1 dose); 11-18 y (catch-upa)
Liechtenstein C 12-15 mon; 11-15 y (catch-upa)
Luxembourg C 13 mon (1 dose)
The Netherlands C 14 mon (1 dose)
Poland C 2-6 mon (first doses); 8 mon - 19 y 
(Second dose) – not funded
Portugal C 12 mon (1 dose)
Spain C 2 + 12 mon (2 doses); 12 y (booster)
Switzerland C 12-15 mon (1 dose); 11-15 y (booster)
United Kingdom
C 3 mon (first of 2 doses)
C & Hib 12-13 mon (Second of 2 doses)
ACWY
14-15 y (booster) - replaces former C 
booster 
17-25 y (catch-upa) 
B 2 + 4 mon (2 doses); 12-13 mon 
(booster) (from first Sept 2015)
Abbreviations: Hib, Haemophilus influenzae type b; IMD, invasive 
meningococcal disease; NIPs, National Immunisation Programmes.
The following European countries have no vaccinations targeting IMD 
recommended in their NIP: Bulgaria, Croatia, Denmark, Estonia, Finland, 
Hungary, Latvia, Lithuania, Malta, Norway, Romania, Slovakia, Slovenia, and 
Sweden.
a Catch-up (eg, if previous was dosed missed).
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breakthroughs are seen among adolescents/students. These 
breakthroughs may cause campus-like outbreaks and would 
result in ‘missed opportunities.’ To combat the loss of 
opportunities, the United Kingdom offered, complementary 
to their MenC adolescent booster, a MenC vaccine to students 
who enter university for the first time and have not received a 
dose of MenC over the age of ten years.26 Moreover, recently, 
the United Kingdom decided to replace their MenC adolescent 
booster and student catch-up by a MenACWY vaccine.26 
This will be discussed in the next section. To conclude, 
due to waning antibody levels after primary immunisation, 
implementation of a MenC adolescent booster is likely to 
extend direct protection and herd protection. 
Enlarging Protection by Introducing a MenACWY Vaccine 
By introduction of a MenACWY vaccine, expanded protection 
can be provided. The first option is to replace primary MenC 
by a MenACWY vaccine in infants, which is likely to be 
cost-saving when the negotiated price in a tender is lower 
for a MenACWY than for the MenC vaccine.17 However, this 
strategy does not target the waning of antibody levels after 
primary infant immunisation. Furthermore, the changing 
epidemiology of MenY and MenW IMD (including outbreaks 
and slight increases of incidence in several other countries) 
is affecting healthy people in all age-groups. Therefore, to 
target the waning immunity and indirectly prevent IMD in all 
age-groups, the second option is to introduce a MenACWY 
booster dose in adolescents. A MenACWY booster results 
in high immune responses that are comparable with a MenC 
booster, irrespectively of how it is conjugated.18,19,27 With 
the current Dutch epidemiology, a MenACWY booster is 
unlikely to be cost-effective.17 However, with the changing 
epidemiology in mind, a MenACWY booster provides broader 
protection, is likely to be cost-effective and has positive 
effects on herd protection.17 In addition, the aforementioned 
cost-effectiveness analyses are based on the list-price of the 
vaccine. When vaccines are used programmatically, tenders 
can significantly reduce the price of a vaccine to be cost-
effective. 
In Canada, the United States, the United Kingdom, Austria, 
and Greece a MenACWY vaccine already is or will be 
implemented in their NIPs as primary immunisation and/
or booster to maintain low carriage rates and enlarge 
meningococcal serogroups protection beyond MenC IMD 
(Table).18,22,26 Moreover, as United Kingdom’s rise in MenW 
IMD (22 in 2009 and 117 in 2014) includes the same virulent 
strain (ST-11) that caused the outbreak of MenC IMD 15 
years ago28 and this same MenW clone was causing the 
epidemics in South America with high case-fatality ratios,29 
the United Kingdom recently decided to replace their MenC 
adolescent booster by a MenACWY booster and subsequently 
perform a catch-up campaign for students to take out carriage 
and induce herd protection. Because the 4CMenB infant 
vaccine provides some protection against the ST-11 strain 
due to a common subcapsular antigen, and the need for 
multiple doses of MenACWY vaccine in infancy, the United 
Kingdom decided not to implement the MenACWY vaccine 
in their infant immunisation programme.23 To conclude, 
implementation of a MenACWY booster would enlarge 
the IMD protection and target the waning immunity after 
primary MenC immunisation. 
Targeting Greatest Burden of Disease by Introducing an 
Infant MenB Vaccine 
MenB IMD still has the highest burden of disease amongst 
infants in the Netherlands. Implementation of the recent 
available 4CMenB vaccine in the NIP should be considered. 
Moreover, it has been demonstrated that the burden of disease 
is not negligible as elevations of MenB IMD occur with 
intervals of 10-25 years.16 Furthermore, despite discussion 
about the strain-coverage of the 4CMenB vaccine, research 
showed that the theoretical effectiveness is sufficient.30-32 
The 4CMenB vaccine is licensed from 2 months of age.7 In 
contrast, the LP2086 vaccine licensed in the United States is 
only approved for individuals 10-25 years of age and not for 
the patient-population in which the highest burden is found.33 
The first regional MenB immunisation campaign globally, 
using 4CMenB, has been realised in 2014 in Quebec, Canada.34 
Also, the United Kingdom has recently decided to introduce 
the 4CMenB vaccine for infants administered on a 2, 4 + 12-
13 months (2+1) schedule (Table).31,35 Although the price is 
not made official, it seems unlikely that it is implemented 
at a cost-effective price.36 With the current relatively low 
incidence of MenB IMD in the Netherlands, 4CMenB, was 
found unlikely to be cost-effective, when administered on a 2, 
3, 4 + 11 months (3+1) schedule.37 Considering, however, the 
periodicity of MenB IMD, the indirect costs of sequelae and 
the possibility to administer at a 2+1 schedule are included in 
cost-effectiveness analyses, MenB IMD has the potential to 
be cost-effective. In addition, clinical studies reported fevers 
after administration of the 4CMenB vaccine.38 Still, this side 
effect can be combatted by administration of paracetamol 
and does not outweigh the health benefits.39 Another possible 
advantage of the 4CMenB vaccine is that there are indications 
that it provides protection against additional serogroups, 
referred to as cross-immunity. To conclude, MenB IMD 
has the highest prevalence and can now be targeted by 
implementing an infant MenB vaccine. 
Recommended Action
Optimisation of the immunisation strategy should be 
considered, because the changing epidemiology of IMD 
potentially targets an extensive group in the near future. 
Since the introduction of the MenC vaccine was successful, 
IMD currently has a relatively low incidence. However, the 
epidemiology is changing. 
From a public health benefit oriented perspective several 
conclusions can be drawn. In order to target IMD in 
the foreseeable future, combat antibiotic resistance and 
reduce healthcare expenditures in industrialised countries, 
implementation of additional IMD vaccines in the NIP should 
be considered. To illustrate, in the Netherlands, introduction 
of a MenB vaccine in infants has priority as it would target 
the highest burden of disease and combat the periodicity of 
MenB IMD. Thereafter, it is important to target the waning 
antibody levels after primary MenC immunisation, which 
can be done by introducing a MenC adolescent booster. 
Then, monitoring and surveillance of IMD should pay extra 
attention to the additional serogroup occurrences in order 
to combat possible abrupt rises in incidence. Therefore, an 
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alternative scenario is to introduce a MenACWY adolescent 
booster, which would provide long-term protection that goes 
beyond MenC prevention. With the changing epidemiology 
in mind, it is likely that a MenACWY booster is as (cost-) 
effective as a MenC booster. 
Implications for Invasive Meningococcal Disease Prevention
Taking into account the burden of meningococcal disease and 
the latest scientific knowledge related to IMD and prevention, 
it appears that in the near future the epidemiology of IMD 
will change. Immunisation remains the best way to prevent 
IMD and additionally reduces healthcare expenditures and 
the use of antibiotics. The present paper suggests options to 
improve the current immunisation policies. 
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